1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Four Major Clinical Trial Readouts To Watch Out For In Q2

 
• By Ayisha Sharma

Four prominent drug candidates are expecting topline mid- or late-stage data over the next few months. With the help of Biomedtracker's Q2 Outlook Report, we take a look at the assets that could help validate some of the companies developing them, from oncology to psychiatry.

The Countdown Has Started For Several Companies To Release Important Data • Source: Alamy

Day One Biopharmaceuticals, LLC expects top-line Phase II data for its lead candidate, DAY101, in June. The pan-RAF kinase inhibitor is under investigation in the FIREFLY-1 study for pediatric low-grade glioma (pLGG), the most frequent type of brain tumor in children.

The US biotech first got hold of the asset from Takeda Pharmaceutical Co. Ltd. in 2020 and Phase I...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

More from R&D